BI Asset Management Fondsmaeglerselskab A S Has $14.93 Million Stock Holdings in The Cooper Companies, Inc. $COO

Key Points

• BI Asset Management Fondsmaeglerselskab A S has reduced its stake in The Cooper Companies, Inc. by 36.3%, now owning approximately 0.09% valued at about $14.9 million.
• Several institutional investors have made significant adjustments to their holdings, with Forum Financial Management LP increasing its stake by 107.3%.
• Analyst ratings for Cooper Companies show a range of opinions, with a consensus rating of "Moderate Buy" and a target price around $96.73.

BI Asset Management Fondsmaeglerselskab A S cut its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 36.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 176,991 shares of the medical device company's stock after selling 101,061 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned 0.09% of Cooper Companies worth $14,929,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of COO. Mariner LLC increased its position in shares of Cooper Companies by 10.4% during the 4th quarter. Mariner LLC now owns 34,142 shares of the medical device company's stock valued at $3,139,000 after purchasing an additional 3,220 shares during the period. Guggenheim Capital LLC grew its holdings in shares of Cooper Companies by 33.1% in the 4th quarter. Guggenheim Capital LLC now owns 6,808 shares of the medical device company's stock worth $626,000 after acquiring an additional 1,694 shares during the last quarter. Forum Financial Management LP grew its holdings in shares of Cooper Companies by 107.3% in the 4th quarter. Forum Financial Management LP now owns 3,840 shares of the medical device company's stock worth $353,000 after acquiring an additional 1,988 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Cooper Companies by 8.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,558,158 shares of the medical device company's stock worth $143,234,000 after acquiring an additional 120,330 shares during the last quarter. Finally, Ossiam grew its holdings in shares of Cooper Companies by 26.0% in the 4th quarter. Ossiam now owns 6,906 shares of the medical device company's stock worth $635,000 after acquiring an additional 1,427 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Down 2.3%

COO traded down $1.7260 during trading on Monday, reaching $73.4940. 402,937 shares of the stock traded hands, compared to its average volume of 2,145,477. The stock has a market cap of $14.70 billion, a price-to-earnings ratio of 35.69, a price-to-earnings-growth ratio of 1.83 and a beta of 1.00. The Cooper Companies, Inc. has a fifty-two week low of $65.00 and a fifty-two week high of $112.38. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.10 and a quick ratio of 1.23. The stock's 50-day simple moving average is $72.18 and its two-hundred day simple moving average is $78.08.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.03. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $995.12 million. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%.The business's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.85 earnings per share. Cooper Companies has set its FY 2025 guidance at 4.050-4.110 EPS. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on COO shares. Robert W. Baird decreased their target price on Cooper Companies from $107.00 to $97.00 and set an "outperform" rating on the stock in a report on Friday, May 30th. BNP Paribas Exane raised Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 target price for the company in a research report on Tuesday, July 22nd. Wells Fargo & Company decreased their target price on Cooper Companies from $118.00 to $93.00 and set an "overweight" rating for the company in a research report on Friday, May 30th. Wall Street Zen cut Cooper Companies from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $76.00 target price (down previously from $110.00) on shares of Cooper Companies in a research report on Friday, May 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $96.73.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.